FDA approves Forest's levomilnacipran for MDD

FDA approved an NDA from Forest Laboratories Inc. (NYSE:FRX) for Fetzima levomilnacipran to treat major depressive disorder (MDD) in adults. The company said the product will be available in the U.S. next quarter. Forest has exclusive rights to develop and commercialize the selective norepinephrine and serotonin reuptake inhibitor (NSRI) in the U.S. and Canada from Laboratoires Pierre Fabre S.A. (Castres, France) under a 2008 deal. ...